Jul. 16 at 10:27 PM
$VNRX [Again] The Company has spent more than a decade developing its core tech, they have secured 90 global patents and have more than 128 pending. They are in discussions presently with more than 12 global diagnostic and liquid biopsy leaders on licensing agreements, and there is precedent here with licensing from Werfen and Hologic. 90-100% Specificity, >80% Detection for Sepsis, Inflammation and Cancers (Various), including Stage-1/2 and ongoing maintenance levels to those in remission, animals and humans. They are targeting
$27B Total Addressable Market (TAM) with globally exclusive technology that is proven, less expensive, more reliable and easily accessible to any functioning hospital globally - yet they sit at
$14M valuation (liquidity), down 90% over the last year as Lind Global unloads stock on its convertible note. Despite the 18mo SP fallout, NO executives have sold - they are only accumulating.
$1.0-1.2 as noted in prior posts, and multiplier upside (IMO).
